Literature DB >> 15153790

Decreased total nitric oxide production in patients with duchenne muscular dystrophy.

Takefumi Kasai1, Kazuhiro Abeyama, Teruto Hashiguchi, Hidetoshi Fukunaga, Mitsuhiro Osame, Ikuro Maruyama.   

Abstract

Plasma nitric oxide (NO) levels in Duchenne muscular dystrophy (DMD) patients were significantly lower than those observed in both healthy controls and in patients with other neuromuscular disorders. The correlation between NO level and ejection fraction was significant (r = -0.384, p = 0.0391) in the DMD group. Disruption of NO systems may contribute to the development of muscular dystrophy and have implications for therapeutic strategies. Copyright 2004 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15153790     DOI： 10.1007/bf02256104

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN： 1021-7770            Impact factor:   8.410


  6 in total

1.  Nitric oxide-dependent attenuation of noradrenaline-induced vasoconstriction is impaired in the canine model of Duchenne muscular dystrophy.

Authors:  Kasun Kodippili; Chady H Hakim; Hsiao T Yang; Xiufang Pan; N Nora Yang; Maurice H Laughlin; Ronald L Terjung; Dongsheng Duan
Journal:  J Physiol       Date:  2018-09-20       Impact factor: 5.182

Review 2.  Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy.

Authors:  Cara A Timpani; Alan Hayes; Emma Rybalka
Journal:  Orphanet J Rare Dis       Date:  2017-05-25       Impact factor: 4.123

3.  Attempting to Compensate for Reduced Neuronal Nitric Oxide Synthase Protein with Nitrate Supplementation Cannot Overcome Metabolic Dysfunction but Rather Has Detrimental Effects in Dystrophin-Deficient mdx Muscle.

Authors:  Cara A Timpani; Adam J Trewin; Vanesa Stojanovska; Ainsley Robinson; Craig A Goodman; Kulmira Nurgali; Andrew C Betik; Nigel Stepto; Alan Hayes; Glenn K McConell; Emma Rybalka
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

4.  Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?

Authors:  Cara A Timpani; Kamel Mamchaoui; Gillian Butler-Browne; Emma Rybalka
Journal:  Antioxidants (Basel)       Date:  2020-12-13

5.  Role of miR-200c in Myogenic Differentiation Impairment via p66Shc: Implication in Skeletal Muscle Regeneration of Dystrophic mdx Mice.

Authors:  Marco D'Agostino; Alessio Torcinaro; Luca Madaro; Lorenza Marchetti; Sara Sileno; Sara Beji; Chiara Salis; Daisy Proietti; Giulia Imeneo; Maurizio C Capogrossi; Francesca De Santa; Alessandra Magenta
Journal:  Oxid Med Cell Longev       Date:  2018-02-13       Impact factor: 6.543

6.  Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.

Authors:  Agnieszka Łoboda; Józef Dulak
Journal:  Pharmacol Rep       Date:  2020-07-20       Impact factor: 3.024
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.